

Julie Parsonnet, MD

IDENTIFYING DATA

George DeForest Barnett Professor in Medicine
Professor of Medicine (Infectious Diseases and Geographic Medicine)
and of Epidemiology and Population Health
Lane Building L134, 300 Pasteur Dr. Stanford, CA 94305-5107
parsonnt@stanford.edu
650-725-4561

EDUCATION

Colleges and universities attended

1975 – 1979 A.B. Harvard College, Cambridge, Massachusetts
1979 – 1983 M.D. Cornell University Medical College, New York, New York

Scholarships and honors

1979 *Magna cum laude* in History and Science, Harvard University
1983 Alpha Omega Alpha, Cornell University
1983 John Metcalf Polk Prize (Highest medical school academic standing over four years), Cornell University
1983 Clarence Coryell Prize (Highest average in Internal Medicine), Cornell University
1983 Alfred Moritz Michaelis Prize Endowment (Efficiency in General Medicine), Cornell University
1983 American Medical Women's Association Scholarship Citation

Post-doctoral and residency training

1983 – 1984 Intern, Internal Medicine, Massachusetts General Hospital
Boston, Massachusetts
1984 – 1986 Resident, Internal Medicine, Massachusetts General Hospital
Boston, Massachusetts
1986 – 1987 Postdoctoral Fellow, Infectious Diseases, Massachusetts General
Boston, Massachusetts
1987 – 1989 Epidemic Intelligence Service, Enteric Diseases Branch, Division of
Bacterial Diseases, Center for Infectious Diseases, Centers for
Disease Control, Atlanta, Georgia

Board eligibility or boards passed, with date(s)

1986 Board Certified, American Board of Internal Medicine
1988 Board Certified, Infectious Diseases

UNIFORMED SERVICE

07/1/87 – 08/15/89 Lieutenant Commander, US Public Health Service

EMPLOYMENT HISTORY

10/01/89 – 08/31/96 Assistant Professor of Medicine
Division of Infectious Diseases and Geographic Medicine
Stanford University School of Medicine

09/01/91 – 8/31/96 –	Assistant Professor of Health Research and Policy Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine
09/01/96 – 04/01/05 –	Associate Professor of Medicine Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine
09/01/96 – 03/31/05 –	Associate Professor of Health Research and Policy Division of Epidemiology Stanford University School of Medicine
10/01/96 – 09/30/97 –	Acting Chief Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine
10/01/98 – 10/31/01	Chief, Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine
11/01/01 - 12/31/06	Senior Associate Dean for Medical Education Stanford University School of Medicine
04/01/05 – 09/04/19	Professor of Health Research and Policy Division of Epidemiology Stanford University School of Medicine
04/01/05 – present	Professor of Medicine Division of Infectious Diseases and Geographic Medicine Stanford University School of Medicine
09/05/19 – present	Professor of Epidemiology and Population Health Stanford University School of Medicine
08/12/19 – 02/28/20	Physician, McMurdo Station University of Texas Medical Branch

UNIVERSITY SERVICE

Stanford University (SU) and School of Medicine (SOM) Service:

1989 – 1995	Admissions Panel, School of Medicine (SOM)
1992 – 1994	Women's Faculty Steering Committee (SU)
1994 – 1995	Steering Committee, Latin American Studies (SU)
1992 – 1995	Ad Hoc Committee for Suitability to Practice Medicine (SOM)
1993 – 1995	Stanford Biosafety Committee (SOM)
1995 – 1997	Committee for Research Integration, Department of Medicine (SOM)
1995 – 1997	Advisory Board, Department of Medicine (SOM)
1999 – 2006	Committee on Courses and Curriculum (SOM)
2000 – 2001	Department of Medicine Finance Committee (SOM)
2002 – 2006	Committee on Performance Assessment and Advising (SOM)
2005 – 2006	Commission on Graduate Education (SU)
2006 – 2007	Executive Committee, International Initiative (SU)
2006 – 2007	Chair, Working Group on International Health (SU)
2009 – 2011	Appointments and Promotions Committee, Dept. of Medicine (SOM)
2010 – 2012	Chair, Search Committee, Director of Population Health Sciences, Stanford Cancer Center (SOM)
2011 – 2013	Director, Immunocompromised Host Service (SOM)

2010 – 2013	Executive Committee, International Policy Studies (SU)
2011 – 2015	Advisory Committee, Bing Overseas Studies (SU)
2011 – 2015	Population Health Sciences Implementation Group (SOM)
2013 – 2015	Committee on Committees, Faculty Senate (SU)
2021 – 2023	
2013 – 2015	Global Development Program Review Committee (SU)
2013 – 2017	Resident Fellow, Robinson House (SU)
2014 – 2018	Member, Committee on Athletics Physical Education and Recreation (SU)
2013 – 2017	Board on Judicial Affairs (SU)
2013 – 2020	Panel for Title IX Hearings (SU)
2013 – 2018	Executive Committee, Interdisciplinary Program on Human Biology (SU)
2017 – 2019	Member, Committee on Libraries (SU)
2000- (13 years to current_	Stanford University Faculty Senate (SU) Vice Chair, 2016-2017 Steering Committee, 2001-2002 and 2016-2017, 2023
2023 –	Ad Hoc Committee on Academic Speech
2023 – 2026	Stanford University Advisory Board

INTERNATIONAL AND NATIONAL SERVICE

Editorial and Journal Review Responsibilities:

1995 – 2015	Editorial Board, <i>Helicobacter</i> , an international journal published by Blackwell Scientific
1997 – 2018	Associate editor, <i>American Journal of Epidemiology</i>
1997 – 2005	Associate editor, <i>American Journal of Medicine</i>

Reviewer for:

American Journal of Epidemiology, American Journal of Tropical Medicine and Hygiene, Cancer, Cancer Causes and Control, Cancer Epidemiology, Biomarkers and Prevention, Cancer Research, Clinical Infectious Diseases, Digestive Diseases and Sciences, Epidemiologic Reviews, Free Radical Research, Gastroenterology, Gut, Journal of American Medicine, Journal of Clinical Gastroenterology, Journal of Clinical Investigation, Journal of Infectious Diseases, Journal of National Cancer Institute, International Journal of Cancer, Helicobacter, International Journal of Epidemiology, The Lancet, The Lancet infectious Diseases, Nature, New England Journal of Medicine, PLOS One, Proceedings of the National Academy USA., Science.

International Committees

2014	International Agency for Research on Cancer Working Group, <i>Helicobacter pylori</i>
2014-	DSMB member, HELPER Study (<i>Helicobacter pylori</i> eradication for gastric cancer prevention), Seoul, South Korea

National Advisory Committees:

1992	Ad hoc member, Epidemiology and Disease Control Study Sections, NIH
------	---

1993	Review Committee for Laboratory of Developmental and Molecular Immunity, NIH
1994– 1995	Member, National Institute of Diabetes and Digestive and Kidney Disease Special Review Committees, NIH
1994	National Institutes of Health, National Cancer Institute Program Project Site Visit
1995 – 1999	Member, Anti-Infective Drugs Advisory Committee, Food and Drug Administration
2000	Consultant, Anti-Infective Drugs Advisory Committee, Food and Drug Administration
2000	Special Advisor, National Institutes of Allergy and Infectious Diseases Council, Section of Microbiology and Immunology
2001	Member, National Institute of Diabetes and Digestive and Kidney Disease Special Review Committee, NIH
2001	Member, Vaccine Advisory Committee, Federal Drug Administration
2007 – 2011	Scientific Advisory Board, Thrasher Research Fund
2011 – 2016	Standing member, MID-B Study Section, NIAID, NIH
2016 – 2018	Co-Chair, Infectious Diseases Research Career Meeting, Infectious Diseases Society of America and NIH
2018 – 2019	Ad hoc Reviewer, Infection, Reproductive, Asthma and Pulmonary Conditions (IRAP) Study Section, NIAID, NIH
2017 – 2020	Ad hoc Reviewer, World Trade Center Health Program, NIOSH
2018 – 2020	Chair, Infectious Diseases Research Career Meeting, Infectious Diseases Society of America and NIH (meeting canceled 2020)
2019	National Academies' Forum on Microbial Threats Workshop Planning Committee
2021	Ad hoc Reviewer, Immune Development in Early Life (IDEaL) study section, NIAID, NIH
2022	IDSA Fellows In Training Needs Assessment Task Force
2022	National Academy of Medicine Gun Violence Task Force
2023	Reviewer, CE-23-006 study section, Strategies to Prevent Firearm-Related Violence and Injuries, CDC
2024-2029	Councilor, American Association of Physicians.

Professional Associations:

Fellow, Infectious Diseases Society of America
 Member, Society for Epidemiologic Research
 Member, American Federation for Clinical Research
 Member, American Society for Clinical Investigation
 Member, Association of American Physicians
 Member, National Academy of Medicine

Volunteer Professional Service:

1990 – 1995, Volunteer attending physician at the Arbor Free Clinic
 2011 -
 1992 – 1995 Affiliated Medical Committee, Planned Parenthood of Santa Clara and San Benito Counties
 1995 – 2000 Board of Directors, Arbor Free Clinic

2006 – 2008	Site Council, Nixon Elementary School
2007 – 2010	Advisory Board, Cardinal Free Clinics
2018 –	Executive Director, SAFE (Scrubs Addressing the Firearms Epidemic)
2020 –	Board of Directors, Doctors for America
2020 –	Gun Violence Prevention Steering Committee, Doctors for America
2021 -	President, Board Chair (SAFE)
2022 -	Vice-President, San José Firearms Safety Fund

POST-DEGREE HONORS AND AWARDS:

1987	United States Public Health Service Award for Foreign Service
1989	United States Public Health Service Unit Commendation
1989	United States Public Health Service Achievement Award
1990 – 1991	Mellon Foundation Fellow, Stanford University
1990 – 1994	Merck, Sharpe & Dohme Clinical Epidemiology Fellowship, Society for Epidemiologic Research
1991 – 1993	Young Investigators Award, Ortho Pharmaceuticals
1993	Institute for Scientific Information, one of the top ten most cited medical papers in 1993 (NEJM 1991;325:1127-31)
1994	Kenneth L. Vosti Teaching Award, Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine
1998	Elected, American Society for Clinical Investigation
1999	Elected, American Epidemiological Society
2000	Induction, Leon G. Smith Infectious Disease Institute Hall of Fame
2001	Pfizer Visiting Professor in Infectious Diseases
2001 – 2016	Listed, “Best Doctors in America”
2001	Henry J. Kaiser Award for Excellence in Preclinical Teaching. Stanford University School of Medicine
2004	Henry J. Kaiser Award for Innovation in Medical Education
2005	Named George DeForest Barnett Professor in Medicine
2011	Maxwell Finland Lectureship, Infectious Diseases Society of America
2013	Falk Lectureship, NIEHS
2018	Elected, Association of American Physicians
2019	Elected National Academy of Medicine

CURRENT GRANTS AND CONTRACTS:

1. Nadeau PI (**Parsonnet Co-Investigator**). SEAL (Stopping Atopic Dermatitis and Allergy) Study (1R01AI147462-01A1). National Institutes of Health 7/1/20 – 6/30-27.
2. **Parsonnet J (PI)** Feasibility of conducting HIV surveillance in community wastewater. (R21 AI179550) 8/23/2023 – 7/31/-2025
3. **Parsonnet J (MPI)** SARS-COV-2 Screening in Dialysis Facilities: Building an Optimal Strategy to Protect High Risk Populations. (5U01AI169477-02). National Institutes of Health 1/11/2022 – 4/30/2024
4. **Parsonnet J (MPI)** Pandemic preparedness for underserved persons in the US: Harnessing data from the RADx-UP consortium to assess public health tools for resource allocation. (R21 MD019394). 09/21/23 – 6/30/2025

PAST GRANTS

1. **Parsonnet J (PI)** The skin microbiome, atopic dermatitis and food allergy. Seed Grant, CHRI, Stanford. 7/1/17 – 6/30/18
2. **Parsonnet J (PI)**. Childhood infection and prevention of obesity. (R01 HD063142). National Institutes of Health 10/1/09-9/30/16 (NCS).
3. Gardner C (**Parsonnet, PI substudy**). Do Genotype patterns predict weight loss success for low carb and low fat diets. Nutrition Science Initiative and National Institutes of Health. 9/1/13 – 9/1/16.
4. **Parsonnet J (PI)**. Effects of probiotics on gut microbiome structure and function in Bangladeshi infants. Stanford Microbiome Seed Grant. 3/1/15 – 8/28/16
5. **Parsonnet J (PI)**. Development of the infant gastrointestinal virome and shedding of oral polio and rotavirus vaccines in Bangladeshi and US infants. Gates Foundation and the Center for Human Systems Biology, Stanford 10/1/2015 – 9/30/2016
6. **Parsonnet J (PI)**. Contaminated Foods, Maternal Infection and Enterotoxigenic *Escherichia coli* Diarrhea in Weanlings. Thrasher Foundation. 12/01/90-11/30/92.
7. **Parsonnet J (PI)**. *H. pylori* and Gastric Cancer. Infectious Diseases Society of America. 07/01/91-06/30/93.
8. **Parsonnet J (PI)**. *H. pylori* and Risk for Gastric Cancer. (R01 CA55764). National Institutes of Health, National Cancer Institute. 09/30/91-08/31/95.
9. **Parsonnet J (Project Director)**. *H. pylori*, Ascorbic Acid and Mutation. (pilot study DK38707). National Institutes of Health, Digestive Disease Center. 09/01/92-08/31/93.
10. **Parsonnet J (PI)**. *H. pylori*, Beta-carotene and Gastric Cancer Precursors. American Cancer Society Junior Faculty Research Award. 07/01/93-06/30/96.
11. **Parsonnet J (PI)**. *H. pylori*, Ascorbic Acid and Gastric Cancer. Merck,
12. **Parsonnet J (PI)**. Intestinal Metaplasia, Ascorbate and *H. pylori*. (R03 CA62108) National Institutes of Health, National Cancer Institute. 09/30/93-09/29/95.
13. **Parsonnet J (PI)**. Preparation for AIDS vaccine evaluation studies. (N01-A1-35173129-3) Family Health International/National Institutes of Health. 11/04/94-11/03/98.
14. **Parsonnet J (PI)**. *H. pylori* and Gastric Preneoplastic Lesions. (R01 CA64788). National Institutes of Health, National Cancer Institute. 06/01/95-03/31/01.
15. **Parsonnet J (PI)**. Gastrin, *H. pylori* and Colorectal Carcinoma. (R03 CA65801). National Institutes of Health, National Cancer Institute. 07/25/95-06/30/97.
16. **Parsonnet J (PI)**. Office of Technology Licensing Incentive Award. 02/01/96-01/31/97.
17. **Parsonnet J (PI)**. Development of a rat model for gastric cancer. Office of Technology and Licensing. Stanford University. 02/01/96-08/31/98.
18. **Parsonnet J (PI)**. Chlamydia *pneumoniae* and Human Cytomegalovirus. American Heart Association. 07/01/96-06/30/99.
19. Shibata A (PI) **Parsonnet J (Co-investigator)**. *H. pylori* phenotype and stomach cancer. (R01 CA73011). National Institutes of Health. 01/01/97-12/31/01.
20. Owens D (PI); **Parsonnet J (Co-PI)**. The study of *H. pylori*. (97SED09763). Centers for Disease Control. 09/30/97-09/30/00.
21. **Parsonnet J (PI)**. Clinical trials of vaccine and non-vaccine interventions for HIV prevention in developing countries. Family Health International/National Institutes of Health. 09/30/98-09/29/99.

22. Stevens D (PI); **Parsonnet J** (Co-PI). International Research and Training in Emerging Diseases. (D4300923). National Institutes of Health, Fogarty Institute. 09/20/97-07/31/05.
23. **Parsonnet J** (PI). Stanford Clinical Research Training Program. (K30 HL04130). National Institutes of Health. 06/01/99-05/31/05.
24. **Parsonnet J** (PI). Functional and Comparative Genomics in Infectious Diseases. (T32 AI07502). National Institutes of Health. 04/01/96-08/31/05.
25. **Parsonnet J** (PI). Immuno-Epidemiology of Tuberculosis Infection. Thrasher Research Fund. 05/01/04-04/30/07.
26. Pizzo P (PI); **Parsonnet J** (Co-investigator). General Clinical Research Center (M01 RR00070). National Institutes of Health. 12/01/01-11/30/07.
27. **Parsonnet J** (PI of subcontract). Epidemiology and Incidence of Barrett's Esophagus. (115-9387-02). Kaiser Permanente. 09/01/02-06/30/07.
28. **Parsonnet J** (PI). GIS for Extant Data: Modeling *H. pylori* GI Tumors. (R01 CA95946). National Institutes of Health. 09/30/02-08/31/07.
29. **Parsonnet J** (PI). Microarrays of Intermediate Endpoints of Gastric Cancer. (PA-01021). National Institute of Health. 09/20/03-08/31/07.
30. **Parsonnet J** (PI). Clinical experiment of *Helicobacter pylori* transmission. (R01 DK/CA53689). National Institutes of Health. 09/01/97-08/30/08.
31. Solnick J (PI). Prevention of Active Tuberculosis by Infection with *Helicobacter pylori*. Gates Grand Challenge Exploration Grant, Gates Foundation (10/22/08-10/21/09)
32. **Parsonnet J** (PI of pilot sub-award). Development of a cell proliferation assay for assessing cell-mediated immunity to infectious diseases in type-2 diabetics
11/1/07 – 10/31/09 [Arvin A (PI) NIH Cooperative Center for Translational Research on Human Immunology and Biodefense The Stanford/Packard Vaccine Center]
33. **Parsonnet J** (PI) Development of a microbial antigen array for multiplex, longitudinal analysis of exposure to infectious agents. Institute for Infection, Transplant and Immunity Seed Grant. 3/15/08 to 3/14/2010.
34. **Parsonnet J** (PI). Is atherosclerosis an infectious disease? Donald E. and Delia B. Baxter Foundation Research Award. 04/01/96-2008
35. **Parsonnet J** (PI) Epidemiology of Emerging Infections and Bioterrorism (T32 AI052073). National Institutes of Health 9/9/09-9/8/14.
36. **Parsonnet J** (PI). Epidemiology of *H. pylori* Transmission. (R01-AI42801). National Institutes of Health. 04/01/99-02/28/13.
37. **Parsonnet J** (PI). Epidemiology of *H. pylori* Transmission. (R01-AI42801-10SIARRA). National Institutes of Health. 07/12/10-02/28/13 .
38. Contopoulos D (PI) Long term antibiotic use and weight gain in children and adolescents. (R03 HD072400). National Institutes of Health 10/01/12 – 9/30/14
Role: Coinvestigator
39. **Parsonnet J** (PI). BMI in the US: integrating infectious diseases into birth cohort, period and age effects in population surveys. Stanford Innovation in Population Medicine Grant. 1/1/12 – 12/31/12
40. **Parsonnet J** (PI). Term Antibiotic Use and Weight Gain in Children and Adolescents. Stanford Innovation in Population Medicine Grant. 9/1/11 – 8/31/12
41. Contopoulos D (**Parsonnet, Co-PI**); Longterm antibiotic use and weight gain in children and adolescents (R03 HD082400). National Institutes of Health 10/01/12 – 9 30/14.

42. **Parsonnet (PI):** Exploratory study of sustainability of probiotic use in Bangladeshi infants. Center for Global Health, Stanford. 5/1/13 – 4/30/2014.
43. **Parsonnet J (PI).** Effects of Probiotics on gut microbiome structure and function in Bangladeshi infants. Stanford Microbiome Seed Grant 1/1/15 to 12/31/15.
44. **Parsonnet J (PI)** Effects of probiotics on gut function, integrity and inflammation in Bangladeshi infants. Stanford ITI Seed Grant 1/1/15 -12/31/15
45. **Parsonnet J (PI).** Probiotics in the US: Integrating consumer reports, physician practices and patient behaviors to determine use patterns and implications. Spectrum Pilot Seed Grant for Population Health Sciences 1/1/15-12/31/15
46. **Parsonnet J (PI).** Household triclosan and triclocarban use in the developing infant microbiota (R21 ES023371). National Institutes of Health 1/14/14 – 12/31/17 (NCX).
47. **Parsonnet J (PI).** Accuracy of weekly self reporting of health care utilization, infectious diseases and antibiotic use among pregnant women and their infants.. Spectrum Pilot Seed Grant for Population Health Sciences 1/1/15-12/31/16
48. **Parsonnet J (PI).** Development of the infant gastrointestinal virome and shedding of oral polio and rotavirus vaccines in Bangladeshi and US children. Gates Foundation and Stanford Center for Human Systems Immunology. 11/1/2015 – 10/31/2017.
49. **Parsonnet J (PI).** Mining the EMR and extant population datasets to define normal human body temperature over time. Spectrum Pilot Seed Grant for Population Health Sciences. 1/1/17 – 12/31/17.
50. **Parsonnet J (PI).** Thyroid function in mothers and babies exposed to triclosan and triclocarban (Contract). Colgate. 12/15/15 – 12/14/17
51. **Han S (Parsonnet Co-PI).** Population-based health information exchange for cancer prevention: surveillance for cancer-related infections. Spectrum Pilot Seed Grant for Learning Health Care Systems. 1/1/17 – 12/31/17.
52. **Parsonnet J (PI).** Bridge grant. STORK. CHRI, Stanford 4/15/18 – 4/13/19
53. **Parsonnet J (PI).** Clinical Epidemiology of Infectious Diseases (T32AI052073).. National Institutes of Health. 7/1/02 - 7/31/22.
54. **Parsonnet J (PI).** Serologic studies for COVID in vulnerable populations. Stanford Center for Innovation in Global Health. 4/30/2021 – 4/29/2021
55. **Parsonnet J (PI).** CALSCOPE: Seroepidemiology survey for COVID with CDPH. Public Health Foundation Enterprises, Inc. Heluna Health. 05/01/2021 – 11/30/2022
56. **Parsonnet J (PI)** CA-FACTS: Solano and Santa Clara County. Public Health Foundation Enterprises, Inc. DBA Heluna Health. 05/01/2021 – 11/31/2022
57. **Parsonnet J (PI).** Longitudinal investigations of the infant virome and its associations with obesity (R01HD088837). National Institutes of Health, 4/1/17 – 6/30/23 (NCX).
58. **Parsonnet J (PI).** Microbiome studies of children in STORK. Max Planck Institute, Tubingen. 12/15/2017 – 1/31/2023 (Contract)
59. **Parsonnet J (PI).** Californians Fighting Coronavirus Together (CA-FACTS). Chan Zuckerberg Biohub. 5/1/2020 – 4/30/2023

PEER-REVIEWED ARTICLES (** more than 1000 citation, **more than 250 citations)

1. **Parsonnet J, Welch K, Compton C, Strauss R, Wang T, Kelsey P, Ferraro MJ.** Simple microbiologic detection of *Campylobacter pylori*. *Journal of Clinical Microbiology* 1988; 26:948-949.

2. **Parsonnet J**, Trock SC, Bopp CA, Wood CJ, Addiss DG, Alai F, Gorelkin L, Hargrett-Bean N, Gunn RA, Tauxe RV. An outbreak of chronic diarrhea associated with drinking untreated water. *Annals of Internal Medicine* 1989; 110:985-991.
3. **Parsonnet J**. Trichosporon beigellii peritonitis. *Southern Medical Journal* 1989; 82:1062-1063.
4. Preblud SR, Tsai TF, Brink EW, Nehlen BL, **Parsonnet J**. International travel and the young child under two years: I. Recommendations for immunization. *Pediatric Infectious Disease Journal* 1989; 8:416-425.
5. Nehlen BL, **Parsonnet J**, Preblud SR, Tsai TF, Brink EW. International travel and the young child under two years: II. Recommendations for prevention of traveler's diarrhea and malaria chemoprophylaxis. *Pediatric Infectious Disease Journal* 1989; 8:735-739.
6. **Parsonnet J**, Greene K, Gerber RA, Tauxe R, Vallejo OJ, Blake P. Shigella dysenteriae type 1 infections in U.S. travelers to Mexico, 1988. *Lancet* 1989; ii:543-545.
7. *Strauss RM, Wang TC, Kelsey PB, Compton CC, Ferraro M, Perez-Perez G, **Parsonnet J**, Blaser MJ. Association of *Campylobacter pylori* infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. *American Journal of Medicine* 1990; 89:464-469.
8. ****Parsonnet J**, Vandersteen D, Goates J, Sibley RK, Pritikin J, Chang Y. *Helicobacter pylori* in intestinal- and diffuse-type gastric adenocarcinoma. *Journal of National Cancer Institute* 1991; 83:640-643.
9. *****Parsonnet J**, Friedman GD, Vandersteen DT, Chang Y, Vogelmann JH, Orentreich N, Sibley R. *Helicobacter pylori* infection and the risk for gastric carcinoma. *New England Journal of Medicine* 1991; 325:1127-1131. PMID:1891020
10. Strockbine NA, **Parsonnet J**, Greene KD, Kiehlbauch JA, Wachsmuth IK. Molecular epidemiologic techniques in analysis of epidemic and endemic Shigella dysenteriae type 1 strains. *Journal of Infectious Diseases* 1991; 163:406-408.
11. Janda RC, Conklin JL, Mitros FA, **Parsonnet J**. Multifocal colitis associated with an epidemic of chronic diarrhea. *Gastroenterology* 1991; 100:458-464.
12. Stommel EW, **Parsonnet J**, Jenkyn LR. Polymyositis induced by the fish toxin ciguatera. *Archives of Neurology* 1991; 48:874-877.
13. ****Parsonnet J**, Blaser M, Perez-Perez G, Hargrett-Bean N, Tauxe RV. Symptoms and risk factors for *Helicobacter pylori* infection in a cohort of epidemiologists. *Gastroenterology* 1992; 102:41-46.
14. *Guarner J, Mohar A, **Parsonnet J**, Halperin DC. The association of *Helicobacter pylori* with gastric cancer and preneoplastic gastric lesions in Chiapas, Mexico. *Cancer* 1993; 71:297-301.
15. Tinoco R, Tinoco R, **Parsonnet J**, Halperin DC. Paraquat poisoning in southern Mexico: A report of 25 cases. *Archives of Environmental Health* 1993; 48:78-80.
16. **Parsonnet J**, Samloff IM, Nelson LM, Orentreich N, Vogelmann JH, Friedman G. *Helicobacter pylori*, pepsinogen and risk for gastric adenocarcinoma. *Cancer Epidemiology, Biomarkers and Prevention* 1993; 2:1-7.
17. Wilson BE, **Parsonnet J**. Azathioprine hypersensitivity mimicking sepsis in a patient with Crohn's disease. *Clinical Infectious Diseases* 1993; 17:940-941.
18. *****Parsonnet J**, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E, Orentreich N, Vogelmann JH, Friedman GD. *Helicobacter pylori* infection and gastric lymphoma. *New England Journal of Medicine* 1994; 330:1267-1271.

19. ***Small PM, Hopewell PC, Singh SP, Paz A, **Parsonnet J**, Ruston DC, Schechter GF, Daley CL, Schoolnik GK. The contemporary urban epidemiology of tuberculosis: a population-based study using conventional and molecular methods. *New England Journal of Medicine* 1994; 330:1703-1709.
20. **Blaser MJ, **Parsonnet J**. Parasitism by the "slow" bacterium *Helicobacter pylori* leads to altered gastric homeostasis and neoplasia (Perspectives). *Journal of Clinical Investigation* 1994; 94:4-8. PMID:PMC296275.
21. Grossman D, Witham N, Burr D, Rubin F, Schoolnik G, **Parsonnet J**. Flagellar serotypes of *Salmonella typhi* in Indonesia: relationships among motility, invasiveness and clinical illness. *Journal of Infectious Diseases* 1995; 172:2122-16.
22. *Replogle ML, Glaser SL, Hiatt RA, **Parsonnet J**. Biological sex as a risk factor for *Helicobacter pylori* infection in young, healthy adults. *American Journal of Epidemiology* 1995; 142:856-863.
23. Replogle ML, Kasumi W, Ishikawa KB, Yang S, Juji T, Miki K, **Parsonnet J**. Increased risk of *Helicobacter pylori* associated with birth in wartime Japan. *International Journal of Epidemiology* 1996; 25:210-214.
24. ****Parsonnet J**, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of *Helicobacter pylori* screening to prevent gastric cancer: a mandate for clinical trials. *Lancet* 1996; 348:150-154.
25. Thorburn CM, Rodriguez L, **Parsonnet J**. Epidemiology of gastric non-Hodgkin's lymphoma patients: parallels with *Helicobacter pylori*. *Helicobacter* 1996; 1:75-78.
26. ****Parsonnet J**, Friedman GD, Orentreich N, Vogelmann JH. Risk for gastric cancer in people with CagA positive or CagA negative *Helicobacter pylori* infection. *Gut* 1997; 40; 297-301. PMID:PMC1027076.
27. Horn-Ross PL, Barnes S, Kirk M, Coward L, **Parsonnet J**, Hiatt RA. Urinary phytoestrogen levels in young women from a multiethnic population. *Cancer Epidemiology Biomarkers & Prevention* 1997; 6:339-345.
28. **Parsonnet J**, Replogle ML, Yang S, Hiatt R. Prevalence of CagA-positive strains among *H. pylori*-infected, healthy young adults. *Journal of Infectious Diseases* 1997; 175:1240-1242.
29. Witherell HL, Hansen S, Jellum E, Orentreich N, Vogelmann JH, **Parsonnet J**. Risk for gastric lymphoma in persons with CagA positive and CagA negative *Helicobacter pylori* infection. *Journal of Infectious Diseases* 1997; 176:1641-1644.
30. Witherell HL, Hiatt RA, Replogle M, **Parsonnet J**. *Helicobacter pylori* infection and excretion of 8-hydroxy-2-deoxyguanosine, an oxidative DNA adduct. *Cancer Epidemiology Biomarkers & Prevention* 1998; 7:91-96.
31. **Thorburn CM, Friedman GD, Vogelmann JH, Orentreich N, **Parsonnet J**. Gastrin and colorectal cancer: a prospective study. *Gastroenterology* 1998; 115:275-280.
32. Solnick JV, Canfield DR, **Parsonnet J**. Rhesus monkey (*Macaca mulatta*) model of *Helicobacter pylori*: non-invasive detection and derivation of specific pathogen-free monkeys. *Lab Animal Medicine* 1999; 49:197-201.
33. Granich R, Cantwell MF, Long K, Maldonado Y, **Parsonnet J**. Patterns of health seeking behavior during episodes of childhood diarrhea: a study of Tzotzil-speaking Mayans in the highlands of Chiapas, Mexico. *Social Science Medicine* 1999; 48:489-495.
34. Harris RA, Owens DK, Witherell H, **Parsonnet J**. *Helicobacter pylori* and gastric cancer: what are the benefits of screening only for the CagA phenotype of *H. pylori*. *Helicobacter* 1999; 4:69-76.

35. Rupnow MF, Schacter R, Owens DK, **Parsonnet J**. *Helicobacter pylori* vaccine development and use: A cost-effectiveness analysis using the Institute of Medicine methodology. *Helicobacter* 1999; 4:272-280.
36. *McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, **Parsonnet J**, Burke RL, and Katzenstein D. Prevalence and incidence of Herpes Simplex Virus Type 2 infection among male Zimbabwean factory workers. *Journal of Infectious Diseases* 1999; 180:1459-1465.
37. ****Parsonnet J**, Shmueli H, Haggerty T. Fecal and oral shedding of *Helicobacter pylori* from healthy infected adults. *Journal of American Medical Association* 1999; 282:2240-2245.
38. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez L, Halperin D, Ley C, **Parsonnet J**. Interobserver variability in application of the revised Sydney classification for gastritis. *Human Pathology* 1999; 30:1431-1434.
39. Shahinian ML, Passaro DJ, Swerdlow DS, **Parsonnet J**. *Helicobacter pylori* is a risk factor for epidemic *Vibrio cholera* 01 infection in Peru. *The Lancet* 2000; 355:377-378.
40. Rupnow MFT, Shachter RD, Owens DK, **Parsonnet J**. A dynamic transmission model for predicting trends in *H. pylori* and associated diseases in the United States. *Emerging Infectious Diseases* 2000; 6:228-237. PMID:PMC2640864.
41. *Liesenfeld O, Montoya JG, Tathineni NJ, Davis M, Brown BW, Cobb KL, **Parsonnet J**, Remington JS. Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive *Toxoplasma* immunoglobulin M antibody titers. *American Journal of Obstetrics Gynecology* 2001; 184:140-145.
42. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez ML, Halperin D, Ley CL, **Parsonnet J**. Gastric atrophy and extent of intestinal metaplasia in a cohort of *Helicobacter pylori*-infected patients. *Human Pathology* 2001; 32:31-35.
43. Shibata A, Longacre TA, Puligandla B, **Parsonnet J**, Habel LA. Histological classification of gastric adenocarcinoma for epidemiologic research: concordance between pathologists. *Cancer Epidemiology Biomarkers and Prevention* 2001; 10:75-78.
44. Passaro DJ, Taylor D, Meza R, Bavrera L, Gilman R, **Parsonnet J**. Acute *H. pylori* infection is followed by an increase in diarrheal disease among Peruvian children. *Pediatrics* 2001; 108:e87.
45. Ley CL, Mohar A, Guarner J, Herrera R, Sanchez ML, Halperin D, **Parsonnet J**. Screening markers for chronic atrophic gastritis in Chiapas, Mexico. *Cancer Epidemiology Biomarkers Prevention* 2001; 10:107-112.
46. ***Helicobacter* and Cancer Collaborative Group (**Parsonnet** is one of over 30 collaborators). Gastric cancer and *Helicobacter pylori*: a combined analysis of 12 case control studies nested within prospective cohorts. *Gut* 2001; 3:347-353.
47. Solnick JV, Hansen LM, Canfield DR, **Parsonnet J**. Determination of the infectious dose of *Helicobacter pylori* during primary and secondary infection in the Rhesus monkey (*Macaca mulatta*). *Infectious Immunology* 2001; 69:6887-6892. PMID:PMC100068.
48. Rupnow MFT, Shachter RD, Owens DK, **Parsonnet J**. Quantifying the population impact of a prophylactic *Helicobacter pylori* vaccine. *Vaccine* 2001; 20:879-885.
49. Goldman JA, Conrad D, Ley CL, Halperin D, Sanchez ML, Villacorta R, **Parsonnet J**. Validation of a Spanish language dyspepsia questionnaire. *Digestive Diseases and Science* 2002; 47:624-640.

50. Shibata A, **Parsonnet J**, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelmann JH, Orentreich N, Habel LA. CagA status of *Helicobacter pylori* infection and p53 gene mutations in gastric adenocarcinoma. *Carcinogenesis* 2002; 23:419424.
51. Passaro DJ, Taylor DN, Gilman RH, Cabrera L, **Parsonnet J**. Growth slowing after acute *Helicobacter pylori* infection is age-dependent. *Journal of Pediatric Gastroenterology & Nutrition* 2002; 35:522-526.
52. Passaro DJ, Hurwitz A, Triadafilopoulos G, **Parsonnet J**. A modification of the quininium resin test for gastric acidity. *Alimentary Pharmacology Therapeutics* 2002; 16:875-880.
53. Mohar A, Ley C, Guarner J, Herrera-Goepfert R, Sanchez L, Halperin D, **Parsonnet J**. High frequency of precancerous lesions of gastric cancer associated with *Helicobacter pylori* and response to treatment, in Chiapas, Mexico. [Spanish] *Gaceta Medica de Mexico* 2002; 138:405-410.
54. Mohar A, Ley C, Guarner J, Herrera-Goepfert R, Sanchez Figueroa L, Halperin D, **Parsonnet J**. Eradication rate of *Helicobacter pylori* in a Mexican population at high risk for gastric cancer and use of serology to assess cure. *American Journal of Gastroenterology* 2002; 97:2530-2535.
55. Guarner J, Herrera-Goepfert R, Mohar A, Sanchez L, Halperin D, Ley C, **Parsonnet J**. Diagnostic yield of gastric biopsy specimens when screening for preneoplastic lesions. *Human Pathology* 2003; 34:28-31.
56. *Fowler RA, Flavin K, Weinacker A, Barr J, **Parsonnet J**, Gould MK. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia: A prospective cohort study. *Chest* 2003; 123:835844.
57. Torres MA, Passaro DJ, Watanabe J, **Parsonnet J**, Small P, Miyagi X, Rodriguez C, Astete X, Walz S, Gilman RA. No association between *Helicobacter pylori* and *Mycobacterium tuberculosis* infections among gastrointestinal clinic attendees in Lima, Peru. *Journal of Epidemiology and Infection* 2003; 130:87-91. PMID:PMC2869942.
58. Witherell HL, Smith KL, Friedman GD, Ley C, Thom DH, Orentreich N, Vogelmann JH, **Parsonnet J**. C-reactive protein, *Helicobacter pylori*, *Chlamydia pneumonia*, cytomegalovirus and risk for myocardial infarction: a prospective study. *Annals of Epidemiology* 2003; 13:170-177.
59. Haggerty TD, Shmueli H, **Parsonnet J**. *Helicobacter pylori* in cathartic stools of subjects with and without hypochlorhydria. *Journal of Medical Microbiology* 2003; 52:189-191.
60. Solnick JV, Chang K, Canfield DR, **Parsonnet J**. Natural acquisition of *Helicobacter pylori* infection in newborn rhesus macaques. *Journal of Clinical Microbiology* 2003; 41:5511-5516. PMID:PMC309038.
61. *Ley C, Mohar A, Guarner J, Herrera-Goepfert R, Sanchez-Figueroa L, Halperin D, Johnstone I, **Parsonnet J**. *Helicobacter pylori* eradication and gastric preneoplastic conditions: A randomized, double-blind, placebo-controlled trial. *Cancer Epidemiology Biomarkers and Prevention* 2004; 13:4-10.
62. **Duck WM, Sobel J, Pruckler JM, Song Q, Swerdlow D, Friedman C, Sulka A, Swaminatha B, Taylor T, Hoestra M, Griffin P, Smoot D, Peek R, Metz DC, Bloom PB, Goldschmidt S, Dunne D, **Parsonnet J**, Triadafilopoulos G, Perez-Perez GI, Cutler A, Vakil N, Ernst P, Czinn S, Gold BD. Antimicrobial resistance rates and risk factors for antimicrobial resistance in *Helicobacter pylori* infection in a prospective

- multi-center study in the US. *Emerging Infectious Diseases* 2004 Jun; 10(6):1088-1094.
63. Perry S, Sanchez ML, Yang S, Haggerty TD, Hurst P, **Parsonnet J**. *Helicobacter pylori* and risk of gastroenteritis. *Journal of Infectious Diseases* 2004; 190:303-310.
 64. *De Martel C, Llosa AE, Farr SM, Friedland GD, Vogelmann JH, Orentreich N, Corley DR, **Parsonnet J**. *Helicobacter pylori* infection and risk of development of adenocarcinoma of the esophagus. *Journal of Infectious Diseases*. J Infect Dis 2005;191:761-7. PMID:15688293.
 65. Nguyen MH, Perry S, **Parsonnet J**. Quantiferon-TB predicts tuberculin skin test boosting in U.S. foreign-born. *International Journal of Tuberculosis and Lung Disease*. 2005;9:985-91.
 66. Garg P, Perry S, Dorn M, Himathongkham S, Hardcastle L, **Parsonnet J**. Risk of intestinal helminth and protozoan infection in a refugee population. *American Journal of Tropical Medicine Hygiene*. 2005;73:386-91.
 67. *Perry S, Sanchez ML, Hurst PK, **Parsonnet J**. Gastroenteritis and transmission of *Helicobacter pylori* in households. *Emerging Infectious Diseases*. J Infect Dis 2005;190:303-10. PMCID:PMC3372328
 68. Haggerty TD, Perry S, Sanchez L, Perez-Perez G, **Parsonnet J**. Significance of transiently-positive stool ELISA tests for *H. pylori* in children. *Journal of Clinical Microbiology*. J Clin Microbiol 2005;43:2220-3. PMCID:PMC1153794.
 69. Garg PK, Perry S, Sanchez L, **Parsonnet J**. Concordance of *Helicobacter pylori* infection among children in extended family homes. *Epidemiology and Infection*. 2005;Nov 11:1-10. PMCID:PMC2870425.
 70. Guarner J, Bartlett J, Seitz R, Whistler T, Herrera-Goepfert R, Mohar A, Sanchez ML, Halperin D, **Parsonnet J**. Cell proliferation and inflammation on biopsy samples with multifocal atrophic gastritis before and 1 year after *Helicobacter pylori* eradication. *Archives of Pathology and Laboratory Medicine*. 2005;129:1451-6.
 71. Tsai CJ, Perry S, Sanchez L, **Parsonnet J**. *Helicobacter pylori* infection in different generations of Hispanics in the San Francisco Bay Area. *American Journal of Epidemiology*. 2005;162:351-7.
 72. Rhee M, Sissoko M, Perry S, McFarland W, **Parsonnet J**, Doumbo O. Use of insecticide-treated nets (ITNs) following a malaria education intervention in Piron, Mali: a control trial with systematic allocation of households. *Malaria* . 2005;4:35. PMCID:PMC1208942.
 73. Van Kerkhove MD, **Parsonnet J**, Weingart M, Tompkins LS. Investigation of coagulase-negative Staphylococci Mediastinitis infection following cardiothoracic surgery. *Infection Control and Hospital Epidemiology* 2006; 27: 305-307.
 74. de Martel C, Ratanasopa S, Passaro D, **Parsonnet J**. Validation of the blood Quininium Resin Test for assessing gastric hypochlorhydria. *Digestive Diseases and Sciences*. 2006;51:84-8. PMID:16416217.
 75. Tsai CJ, Herrera-Goepfert R, Tibshiran RJ, Yang S, Mohar A, Guarner J, **Parsonnet J**. Changes of gene expression in gastric preneoplasia following *Helicobacter pylori* eradication therapy. *Cancer Epidemiology Biomarkers and Prevention*. 2006;15:272-80. PMID: 16492915
 76. *deMartel C, **Parsonnet J**. *Helicobacter. pylori* infection and gender: a metaanalysis of population-based prevalence surveys. *Digestive Diseases and Sciences* 51:2292-301. PMID:17089189.

77. Lentine KL, **Parsonnet J**, Taylor I, Wrone EM, Lafayette RA. Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.. *Clin Exp Nephrol* . 2006 Mar;10(1):55-62.
78. Perry S, Sanchez ML, Yang S, Haggerty TD, Hurst PK, Perez-Perez G, **Parsonnet J** . Gastroenteritis and transmission of *Helicobacter pylori* infection in households.. *Emerging Infectious Diseases* 2006;12(11):1701-2.
79. Solnick, JV, Fong J, Hansen LM, Chang K, Canfield DR, **Parsonnet J**. Acquisition of *Helicobacter pylori* infection in Rhesus macaques is most consistent with oral-oral transmission. *J Clin Microbiol*. 2006;10:3799-803. PMID:PMC1594807.
80. De Martel C, Haggerty TD, Corley DA, Vogelmann JH, Orentreich N, **Parsonnet J**. Serum ghrelin levels and risk of subsequent adenocarcinoma of the esophagus. *Am J Gastroenterol* 2007;102(6):1166-72. PMID17378911.
81. Cheshier SH, Bababeygy SR, Higgins D, **Parsonnet J**, Huhn SL. Cerebral myiasis associated with angiosarcoma of the scalp: Case report. *Neurosurgery* 2007;1:E167.
82. Choy M, Switzer P, de Martel C, **Parsonnet J**. Estimating disease prevalence using census data. *Epidemiology and Infection* 2007 Nov 30;1-8. PMID: PMC2870920.
83. *Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, **Parsonnet J**. *Helicobacter pylori* infection and the risk of Barrett's oesophagus. *Gut* 2008;57(6):727-33. PMID:PMC2670583.
84. *Perry S, Sanchez ML, Yang S, Agarwal Z, Hurst P, **Parsonnet J**. Reproducibility of QuantiFERON®-TB GOLD In-tube Assay. *Clinical and Vaccine Immunology* 2008;15(3):425-32. PMID:PMC2268272. (Cited by Faculty of 1000)
85. De Martel C, Llosa AE, Friedman GD, Vogelmann JH, Orentreich N, Stolzenberg-Solomon RZ, **Parsonnet J**. *Helicobacter pylori* infection and development of pancreatic cancer. *Cancer Epidemiol Biomarkers Prevention* 2008;17:1188-94. PMID: 18483341.
86. *Chiu C, Greninger A, Haggerty T, Kwok T, Kanada K, Louie J, Shigeo Y, Schnurr D, **Parsonnet J**, Ganem D, DeRisi J. Identification of novel cardioviruses related to Theiler's murine encephalomyelitis viruses in human cases of gastroenteritis and other illnesses. *PNAS*. 2008 105:14124-14129. PMID: PMC2528868.
87. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, **Parsonnet J**. *Helicobacter pylori* infection and gastroesophageal reflux disease: a case-control study. *Helicobacter* 2008;13:35260.
88. De Martel C, Plummer M, **Parsonnet J**, van Doorn L, Franceschi S. *Helicobacter* species in cancers of the gallbladder and extra-hepatic biliary tract. *Br J Cancer*. 2009;100:194-9. PMID:PMC2634699
89. *Greninger A, Runckel C, Chiu C, Haggerty T, **Parsonnet J**, Ganem D, DeRisi J. The complete genome of Klassevirus—a novel picornavirus in pediatric stool. *Virology* 2009;6:82 PMID: PMC2709156
90. Rupnow MFT, Chang AH, Shachter RD, Owens DK, **Parsonnet J**. Cost-effectiveness of a potential prophylactic *Helicobacter pylori* vaccine in the United States. *J Infect Dis*. 2009;200:1331-7 . PMID: 19751153.
91. *Perry S, de Jong BC, Solnick JV, Sanchez ML, Yang S, Lin PL, Hansen LM, Talat N, Hill PC, Hussain R, Adegbola RA, Fynn J, Canfield D, **Parsonnet J**. Infection with *Helicobacter pylori* is associated with protection against tuberculosis. *PLOS One*. 2010;5:e8804. PMID: PMC2808360 (Cited by Faculty of 1000)

92. **Parsonnet J**, Gruppuso PA, Kanter S, Boninger M .Required vs. elective research and in-depth scholarship program in the medical school curriculum. *Academic Medicine*. 2010;85:405-8. PMID:20182112.
93. Green EP, Borkan JM, Pross SH, Adler SR, Nothnagle M, **Parsonnet J**, Gruppuso PA. Encouraging scholarship: Medical school programs to promote student inquiry beyond the traditional medical curriculum. *Academic Medicine*. 2010;85:409-18. PMID:20192113.
94. Laskowitz DT, Drucker RP, **Parsonnet J**, Cross PC, Gesundheit N. Engaging students in dedicated research and scholarship during medical school: the longterm experiences at Duke and Stanford. *Academic Medicine*. 2010;85:419-28. PMID 20192114.
95. *Talat N, Perry S, **Parsonnet J**, Dawood G, Hussain R. Vitamin D is associated with tuberculosis disease progression in a hyperendemic setting. *Emerging Infect Dis*. 2010; 16;853-5. PMID: 20409383.
96. Chiu CY, Greninger A, Chen E, Haggerty T, **Parsonnet J**, Busch M, Delwart E, DeRisi J, Ganem D. Cultivation and serological characterization of a human Theiler's-like Cardiovirus associated with diarrheal disease. *J. Virol*. 2010;84:4407-14. PMCID: PMC2863762
97. Herrera V, Yeh E, Murphy K, **Parsonnet J**, Banaei N. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay. *J Clin Microbiol* 2010;48:2672-6 PMID: 20519472.
98. Chang AH, Haggerty TD, Leung C, de Martel C, **Parsonnet J**. Effect of *Helicobacter pylori* infection and gastric acidity on gastroenteritis due to enteropathogenic *Escherichia coli*. *Dig Dis Sci* 2011;56:457-64. PMID:20635147.
99. Pepperell C, Chang AH, Wobeser W, **Parsonnet J**, Hoepfner VH. Local epidemic history as a predictor of tuberculosis incidence in Saskatchewan Aboriginal communities." *Int J Tuberc Lung Dis* 2011;(15):899-905. PMCID:PMC3292043.
100. Chang ET, Fish K, Schupp CW, **Parsonnet J**, DeRouen MC, Keegan THM, Clarke CA, Glaser SL, Gomez SLL. Gastric cancer incidence among Hispanics in California: patterns by time, nativity and neighborhood characteristics. *Cancer Epidemiol Biomarkers and Prevention*. 2012;21:709-19 PMID:22374991
101. Suh G, Ley C, **Parsonnet J**. Infectious diseases in children and body mass index in young adults. *EID*. 2012;18:1490-2. PMID:22785197; PMC3437733.
102. Lankester J, Perry S, **Parsonnet J**. A Method for Adjusting Self-Reported Dietary Recall. *Amer J Nutrition* Submitted for publication.
103. Perry S, Chang AH, Sanchez ML, Yang S, Haggerty TD, **Parsonnet J**. The immune response to TB infection in the setting of *Helicobacter pylori* and helminth infections. *Epidemiol Infect*. 2012;7:1-12. PMID:22954328
104. Slater M, **Parsonnet J**, Banaei N. Investigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay. *J Clin Micro*. 2012;50:3105-7 PMID:22785197 PMC3421800.
105. *Yu G, Greninger A, Isa P, Phan TG, Sanchez ML, **Parsonnet J**, Miller S, DeRisi J, Delward E, Arias C, Chiu CY. Discovery of a Novel Polyomavirus in Acute Diarrheal Samples from Children. *PLOS One*. 2012;7(11):e49449. PMID: 23166671; PMC3498111
106. Chang AH, Perry S, Du J, Agunbiade A, Polesky A, **Parsonnet J**. Decreasing intestinal parasites in recent Northern California refugees. *Am J Trop Med Hygiene*. .2013;88:191-7. PMID:23149583, PMC3541735.

107. Lankester J, Patel C, Cullen MR, **Parsonnet J**. Urinary triclosan is associated with elevated body mass index in NHANES. *PloS One*; 2013. **8**(11): p. e80057. PMID 24278238. PMCID: PMC3836985
108. Shaw GM, Wise PH, Mayo J, Carmichael SL, Ley C, Lyell DJ, Shachar BZ, Melsop K, Phibbs CS, Stevenson DK, **Parsonnet J**, Gould JB. Maternal body mass and risk for preterm birth by race/ethnic and education background. *Paediatric and perinatal epidemiology*. 2014;28:302-11. PMID:24810721.
109. Slater M, Welland G, Pai M, **Parsonnet J**, Banaei N. Description of an academic institution's experience with the Quantiferon Gold In-Tube test for latent tuberculosis screening in health care workers.. *Am J Respir Crit Care Med* 2013;188:1005-10. PMID 23978270. PMCID: PMC3826285.
110. Lankester J, Perry S, **Parsonnet J**. Comparison of two methods—regression predictive model and intake shift model—for adjusting self-reported dietary recall of total energy intake of populations. *Frontiers in Public Health*. 2014;2:249. Doi:10.3389/fpubh.2014.00249 ecollection 2014. PMCID: PMC4245891.
111. Slater M, Tran MC, Platt L, Luu LT, Phan HT, Pham PT, Guyen HT, Gaur R, **Parsonnet J**, Cattamanchi A, Luo R, Nahid P, Banaei N. In vitro immunomodulation for enhancing T cell-based diagnosis of *M. tuberculosis*. *Diagn Microbiol Infect Dis*. 2015;83:41-5. PMID 26081239..
112. Hoy-Schulz Y, Jannat K, Roberts T, Zaidi SH, Unicomb L, Luby S, **Parsonnet J**. Safety and acceptability of *Lactobacillus reuteri* DSM 17938 and *Bifidobacterium longum* subspecies *infantis* 35624 in Bangladeshi infants: a phase I randomized clinical trial. *BMC Complementary and Alternative Medicine*. 2016;16:44. PMCID: PMC4736167
113. Contopoulos-Ioannidis D, Ley C, Wang W, Ma T, Olson C, Shi X, Luft H, Hastie T, **Parsonnet J**. Effect of long term antibiotic use on weight in adolescents with acne. *J Antimicrob Chemotherapy*. 2016; Epub ahead of print. PMID:26782773
114. Ley C, Sanchez ML, Mathur A, Yang Sh, Sundaram V, **Parsonnet J**. Cohort profile: Stanford's Outcomes Research In Kids (STORK)—A prospective study of healthy women and their babies in Northern California. *BMJ Open*. 2016;6:e010910. PMCID: PMC4838723.
115. Poole A**, Pischel L**, Ley C, Suh G, Goodrich J, Haggerty T, Ley R, **Parsonnet J**. Effect of personal care products containing triclosan on the microbiome: a crossover control study. *mSphere*. 2016;18:1(3). Pii:e00056-15. PMCID: PMC4888890.
116. Draper K, Ley C., **Parsonnet J**. A survey of probiotic use practices among patients at a tertiary medical centre. *Benef Microbes*. 2017 May 30;8(3):345-351. doi: 10.3920/BM2016.0148. PMID:28403649.
117. Draper K, Ley C, **Parsonnet J**. Probiotic guidelines and physician practice: a cross-sectional survey and review of the literature. *Beneficial Microbes*. 2017;8(4):507-519. PMID 28618862.
118. Ribado JV, Ley C, Haggerty TD, Tkachenko E, Bhatt AS, **Parsonnet J**. Household triclosan exposure more dramatically impacts the adult microbiome than the infant microbiome: a longitudinal interventional study of household triclosan exposure on the maternal and infant intestinal microbiome. *EMBO Molecular Medicine*. 2017;9:1732-1741. PMID 29040159
119. Ley C, Pischel L. **Parsonnet J**. Triclosan and triclocarban exposure and thyroid hormones during pregnancy—a randomized intervention. *Reproductive Toxicology*. 2017;74:143-149. PMID 28939492

120. Ley C, Sundaram V, Sanchez ML, Desai M, **Parsonnet J**. Triclosan exposure and risk of infection in infants. *PLoS One*. 2018;13:30199298. PMID 29953463..
121. Alarid-Escudera F, Enns EA, Maclehose RF, **Parsonnet J**, Torres J, Kuntz KM. Force of infection of *Helicobacter pylori* in Mexico: Evidence from a national survey using a hierarchical Bayesian model. *Epidemiol Infect*. 2018;146:961-969. PMID 5997526
122. Roberts TJ, Hoy-Schulz YE, Jannat K, **Parsonnet J**. Evidence of inflated exclusive breastfeed estimates from a clinical trial in Bangladesh. *International Breast Feeding Journal*. 2018;doi:10.1186s/1306-018-017904. PMID 30159001
123. Ley C, Willis L, de la Luz Sanchez M, **Parsonnet J**. Recall accuracy of weekly automated surveys of health care utilization and infectious disease symptoms among infants over the first year of life. *PLoS One*. 2019 Dec 17;14(12):e0226623. PMID: 31846482; PMCID: PMC6917293.
124. Wagar LE, Bolen CR, Sigal N, Lopez Angel CJ, Guan L, Kirkpatrick BD, Haque R, Tibshirani RJ, **Parsonnet J**, Petri WA Jr, Davis MM. Increased T Cell Differentiation and Cytolytic Function in Bangladeshi Compared to American Children. *Front Immunol*. 2019 Sep 20;10:2239.. PMID: 31620139; PMCID: PMC6763580.
125. Aibana O, Huang CC, Aboud S, ... **Parsonnet J** among 35 authors.. Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. *PLoS Med*. 2019 Sep 11;16(9):e1002907. PMID: 31509529; PMCID: PMC6738590.
126. Song M, Rabkin CS, Torres J, Kemp TJ, Zabaleta J, Pinto LA, Hildesheim A, Sánchez-Figueroa L, Guarner J, Herrera-Goepfert R, **Parsonnet J**, Camargo MC. Circulating inflammation-related markers and advanced gastric premalignant lesions. *J Gastroenterol Hepatol*. 2019 May;34(5):852-856. PMID: 30357905.
127. Nielsen SCA, Roskin KM, Jackson KJL, Joshi SA, Nejad P, Lee JY, Wagar LE, Pham TD, Hoh RA, Nguyen KD, Tsunemoto HY, Patel SB, Tibshirani R, Ley C, Davis MM, **Parsonnet J**, Boyd SD. Shaping of infant B cell receptor repertoires by environmental factors and infectious disease. *Sci Transl Med*. 2019 Feb 27;11(481). pii: eaat2004. PMID: 30814336; PMCID: PMC6733608.
128. Grembi JA, Nguyen LH, Haggerty TD, Gardner CD, Holmes SP, **Parsonnet J**. Gut microbiota plasticity is correlated with sustained weight loss on a low-carb or low-fat dietary intervention. *Sci Rep*. 2020 Jan 29;10(1):1405. PMID: 31996717; PMCID: PMC6989501.
129. Protsiv M, Ley C, Lankester J, Hastie T, **Parsonnet J**. Decreasing human body temperature in the United States since the industrial revolution. *Elife*. 2020 Jan 7;9. pii: e49555. PMID: 31908267; PMCID: PMC6946399.
130. Martinez L, Cords O, Horsburgh CR, Andrews JR, Pediatric TB Contact Studies Consortium (**Parsonnet** member). The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. *Lancet* 2020;395:973-84. PMID 32199484. PMCID PMC7289654.
131. Tan SK, Granados A, Bouquet J, Hoy-Schulz YE, Green L, Federman S, Stryke D, Haggerty TD, Ley C, Yeh M, Maldonado YA, Andino R, Chiu C, **Parsonnt J**. Metagenomic sequencing of stool samples in Bangladeshi infants: virome association with poliovirus shedding after oral poliovirus vaccination. *Scientific Reports*. 2020 **10**, 15392. <https://doi.org/10.1038/s41598-020-71791-4>. PMID 32958861. PMCID PMC7506025.

132. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, **Parsonnet J**, Chertow GM. Seroprevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA. *Lancet*. 2020 Sep 25;396(10259):1335-1344. PMID 32987007. PMCID PMC7518804
133. Rosser JI, Roltgen K, Dymock M, Shephard J, Martin A, Hogan C, Blomkalns A, Mathew R, **Parsonnet J**, Pinsky B, Maldonado Y, Boyd SD, Chang S, Holubar M. SARS-CoV-2 seroprevalence in healthcare workers in northern California early in the COVID-29 pandemic. *Infect Control Hosp Epidemiol*. 2020 Dec 9:1-7. PMID: 33292895 PMCID: [PMC7783083](https://pubmed.ncbi.nlm.nih.gov/33292895/)
134. Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, **Parsonnet J**, Andrews JR, Weiskopf D, Sette A, Pinsky BA, Singh U, Banaei N. Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. *Clin Infect Dis*. 2020 Oct 9:ciaa1537. doi: 10.1093/cid/ciaa1537. PMID: 33035306
135. Zhang H, Sanidad KZ, Zhu L, **Parsonnet J**, Haggerty TD, Zhang G., Cai Z. Frequent occurrence of triclosan hydroxylation in mammals: A combined theoretical and experimental investigation. *J Hazard Mat* 2020;407:124803. PMID:33338815.
136. Dang R, Schroeder AR, Patel AI., **Parsonnet J**, Wang M. Temperature Measurement at Well-Child Visits in the United States. *J Peds*. 2021. DOI:<https://doi.org/10.1016/j.jpeds.2021.01.045>. PMID: 33508277.
137. Jagannathan P, Andrews J, Bonilla H, Hedlin H, Jacobson K, Balasubramanian V, Purington N, Kamble S, DeVries C, Quintero O, Feng K, Ley C, Winslow D, Newberry J, Maldonado Y, Bhatt A, Wang T, Khosla C, Pinsky B, Desai M, **Parsonnet J**, Singh U. Peg-interferon lambda for treatment of patients with uncomplicated COVID-19: a randomized, placebo-controlled trial. *Nat Commun*. 2021;12(1):1967. Epub 2021/04/01. doi: 10.1038/s41467-021-22177-1. PubMed PMID: 33785743; PMCID: PMC8009873.
138. Anand S, Montez-Rath ME, Han J, Garcia P, Bozeman J, Kerschmann R, Beyer P, **Parsonnet J**, Chertow GM. Laboratory correlates of SARS-CoV-2 seropositivity in a nationwide sample of patients on dialysis in the U.S. *PLoS One*. 2021;16(4):e0249466. Epub 2021/04/16. doi: 10.1371/journal.pone.0249466. PubMed PMID: 33857168; PMCID: PMC8049224
139. Yang F, Nielsen SCA, Hoh RA, Röltgen K, Wirz OF, Haraguchi E, Jean GH, Lee JY, Pham TD, Jackson KJL, Roskin KM, Liu Y, Nguyen K, Ohgami RS, Osborne EM, Nadeau KC, Niemann CU, **Parsonnet J**, Boyd SD. Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues. *Science*. 2021;372(6543):738-41. Epub 2021/04/14. doi: 10.1126/science.abf6648. PubMed PMID: 33846272; PMCID: PMC8139427.
140. Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, Kerschmann R, Beyer P, Boyd SD, Chertow GM, **Parsonnet J**. Serial SARS-CoV-2 Receptor-Binding Domain Antibody Responses in Patients Receiving Dialysis. *Ann Intern Med*. 2021. Epub 2021/05/18. doi: 10.7326/m21-0256. PubMed PMID: 34000201.
141. Garcia P, Montez-Rath ME, Moore H, Flotte J, Fults C, Block MS, Han J, Dittrich M, **Parsonnet J**, Chertow GM, Block GA, Anand S. SARS-CoV-2 Vaccine Acceptability in Patients on Hemodialysis: A Nationwide Survey. *J Am Soc Nephrol*. 2021. Epub 2021/05/01. doi: 10.1681/asn.2021010104. PubMed PMID: 33927004.
142. Wang G, Zhang H, Zhang J, Sanidad KZ, Yeliseyev V, **Parsonnet J**, Haggerty TD, Yang H, Ai L, Xie M, Cai Z, Zhang G. Metabolic fate of environmental chemical triclocarban in colon tissues: roles of gut microbiota involved. *Sci Total Environ*.

- 2021;787:147677. Epub 2021/05/19. doi: 10.1016/j.scitotenv.2021.147677. PubMed PMID: 34004538.
143. Jacobson KB, Pinsky BA, Rath MEM, Wang H, Miller JA, Skhiri M, Shepard J, Mathew R, Lee G, Bohman B, **Parsonnet J***, Holubar M* [*equal contributors]. Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center. *Clin Infect Dis*. 2021. PMID 34137815.
 144. Anand S, Montez-Rath M, Han J, Garcia P, Cadden L, Hunsader P, Kerschmann R, Beyer P, Dittrich M, Block G, Boyd S, **Parsonnet J**, Chertow G. Antibody Response to COVID-19 Vaccination in Patients Receiving Dialysis. *J Am Soc Nephrol*. 2021 Jun 11:ASN.2021050611. doi: 10.1681/ASN.2021050611. Epub ahead of print. PMID: 34117129.
 145. Anand S, Montez-Rath M, Han J, Cadden L, Hunsader P, Kerschmann R, Beyer P, Boyd SD, Garcia P, Dittrich M, Block GA, **Parsonnet J**, Chertow GM. Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic. *JAMA Netw Open*. 2021 Jul 1;4(7):e2116572. doi: 10.1001/jamanetworkopen.2021.16572. PMID: 34251441; PMCID: PMC8276082.
 146. Bunning B, Hedlin H, Purington N, Sundaram V, Kapphahn K, Weng Y, Cunanan K, Maldonado Y, Singh U, Khosla C, O'Hara R, Nicolls M, Springman E, **Parsonnet J**, Rogers A, Levitt J, Desai M. The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial. *Contemp Clin Trials*. 2021 Jul 15;108:106509. doi: 10.1016/j.cct.2021.106509. Epub ahead of print. PMID: 34274494; PMCID: PMC8282451.
 147. Verma R, Kim E, Martínez-Colón GJ, Jagannathan P, Rustagi A, **Parsonnet J**, Bonilla H, Khosla C, Holubar M, Subramanian A, Singh U, Maldonado Y, Blish CA, Andrews JR. SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples. *Open Forum Infect Dis*. 2021 Jun 11;8(7):ofab310. doi: 10.1093/ofid/ofab310. PMID: 34295944; PMCID: PMC8291522.
 148. Jacobson KB, Purington N, **Parsonnet J**, Andrews J, Balasubramanian V, Bonilla H, Edwards K, Desai M, Singh U, Hedlin H, Jagannathan P. Inflammatory but not respiratory symptoms are associated with ongoing upper airway viral shedding in outpatients with uncomplicated COVID-19. *Diagn Microbiol Infect Dis*. 2021 Nov 28;102(3):115612. doi: 10.1016/j.diagmicrobio.2021.115612. Epub ahead of print. PMID: 34974350; PMCID: PMC8627385.
 149. Anand S, Montez-Rath ME, Han J, Garcia P, Cadden LC, Morgan C, Hunsader P, Beyer P, Kerschmann R, Dittrich M, Block G, Chertow GM, **Parsonnet J**. SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. *Ann Intern Med*. 2022 Mar;175(3):371-378. doi: 10.7326/M21-4176. PMID 34904856, PMCID: PMC8722718
 150. Zhang J, Walker ME, Sanidad KZ, Zhang H, Liang Y, Zhao E, Chacon-Vargas K, Yelisseyev V, **Parsonnet J**, Haggerty TD, Wang G, Simpson JB, Jariwala PB, Beaty VV, Yang J, Yang H, Panigrahy A, Minter LM, Kim D, Gibbons JG, Liu L, Li Z, Xiao H, Borlandelli V, Overkleeft HS, Cloer EW, Major MB, Goldfarb D, Cai Z, Redinbo MR, Zhang G. Microbial enzymes induce colitis by reactivating triclosan in the mouse gastrointestinal tract. *Nat Commun*. 2022 Jan 10;13(1):136. doi: 10.1038/s41467-021-27762-y. PMID: 35013263.
 151. Garcia P, Anand S, Han J, Montez-Rath M, Sun S, Shang T, **Parsonnet J**, Chertow G, Schiller B, Abra G. COVID19 vaccine type and humoral immune

- response in patients receiving dialysis. *J Am Soc Nephrol.* 2022 Jan;33(1):33-37. doi: 10.1681/ASN.2021070936. Epub 2021 Oct 13. PMID: 34645698
152. Murugesan K, Jagannathan P, Altamirano J, Maldonado YA, Bonilla HF, Jacobson K, **Parsonnet J**, Andrews JR, Shi RZ, Boyd S, Pinsky BA, Singh U, Banaei N. Long Term Accuracy of SARS-CoV-2 Interferon- γ Release Assay and its Application in Household Investigation. *Clin Infect Dis* 2022;75:e314-e21. PMID: PMC8807306
 153. Holubar M, Subramanian A, Purington N, Hedlin H, Bunning B, Walter KS, Bonilla H, Boumis A, Chen M, Clinton K, Dewhurst L, Epstein C, Jagannathan P, Kaszynski R, Panu L, **Parsonnet J**, Ponder EL, Quintero O, Sefton E, Singh U, Soberanis L, Truong H, Andrews JR, Desai M, Khosla C, Maldonado Y. Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial. *Clin Infect Dis.* 2022 75(11);1883-1892. PMID: PMC9047233
 154. Mehotra ML, Lim E, Lambda K, Kamali A, Lai KW, Meza E, Szeto I, Robinson P, Tsai J, Gebhart D, Fonseca N, Martin AB, Ley C, Quarre T, Scherf S, Watt J, Seftel D, **Parsonnet J**, Jain S. CalScope: Monitoring SARS-CoV-2 Seroprevalence from Vaccination and Prior Infection in Adults and Children in California May 2021– July 2021. *Open Forum Infect Dis* 2022;9:ofac246. PMID: PMC9129171.
 155. Nataranjan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, Park RM, Han A, Schmidtke DT, Verma R, Jacobson KB, **Parsonnet J**, Bonilla HF, Singh U, Pinsky BA, Andrews J, Jagannathan P, Bhatt AS. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection in COVID-19. *Med.* 2022 PMID: 35445682, PMID: PMC9005383.
 156. Richardson SC, Kohn MA, Bollyky J, **Parsonnet J**. Validity of at-home rapid antigen lateral flow assay and artificial intelligence read to detect SARS-CoV-2. *Diagn Microbiol Infect Dis* 2022;104:115763. PMID: 36070629. PMID: PMC9259514.
 157. Hu Z, van der Ploeg K, Chakraborty S, Arunachalam P, Martinez Mori D, Jacobson KB, Bonilla H, **Parsonnet J**, Andrews J, Holubar M, Subramanian A, Khosla C, Maldonado Y, Hedlin H, de la Parte L, Press KD, Ty M, Tan GS, Blish CA, Takahashi S, Rodriguez-Barraquer I, Greenhouse B, Butte AJ, Singh U, Pulendran B, Wang TT, Jagannathan P. Early immune markers of clinical, virologic, and immunologic outcomes in patients with COVID-19: a multi-omics study. *Elife* 2022;11. PMID: PMC9566856.
 158. Garcia, P, Han J, Montez-Rath M, Sun S, Shang T, **Parsonnet J**, Chertow G, Anand S, Abra G, Schiller B. SARS-CoV2 booster vaccine response among patients receiving dialysis. *Clin J Am Soc Nephro* 2022 17(7);1036-1038. PMID: PMC9269633.
 159. Van der Ploeg K, Kiro Singh AS, Mori DAM, Chakraborty S, Hu Z, Jacobson KB, Bonilla H, **Parsonnet J**, Andrews J, Hedlin H, Dantzler K, Ty M, Ruiz-Betancourt D, de la Parte L, Tan GS, Blish CA, Takahashi S, Rodriguez-Barraquer I, Greenhouse B, Singh U, Wang TT, Jagannathan P. TNF α -producing CD4⁺ T cells dominate the SARS-CoV-2-specific memory T cell response in COVID-19 outpatients and are associated with durable antibodies. *Cell Rep Med* 2022;3:100640. PMID: PMC9061140
 160. Montez-Rath ME*, Garcia P, Han J, Cadden LC, Hunsader P, Morgan C, Kerschmann R, Beyer P, Dittrich M, Block GA, Anand S*, **Parsonnet J***, Chertow GM* (*equal contributors). SARS-CoV-2 infection during the Omicron surge among patients receiving dialysis: the role of circulating receptor-binding domain antibodies

- and vaccine doses. *J Am Soc Nephrol* 2022. PMID: 35973733. PMCID: PMC9528334
161. Bennett CL, Clay CE, Siddiqi KA, Olatosi BA, **Parsonnet J**, Camargo JCA. Characteristics of California Emergency Departments in Centers for Disease Control and Prevention-Designated HIV Priority Counties. *J Emerg Med*. 2023 Jan;64(1):93-102. doi: 10.1016/j.jemermed.2022.10.020. Epub 2023 Jan 15. PMID: 36650074; PMCID: PMC10208592.
 162. Walters WA, Granados AC, Ley C, Federman S, Stryke D, Santos Y, Haggerty T, Sotomayor-Gonzalez A, Servellita V, Ley RE, **Parsonnet J***, Chiu CY* [*co-senior authors]. Longitudinal comparison of the developing gut virome in infants and their mothers. *Cell Host Microbe*. 2023 Feb 8;31(2):187-198.e3. doi: 10.1016/j.chom.2023.01.003. PMID: 36758519; PMCID: PMC9950819.
 163. Pinto Y, Frishman S, Turjeman S, Eshel A, Nuriel-Ohayon M, Shrossel O, Ziv O, Walters W, **Parsonnet J**, Ley C, Johnson EL, Kumar K, Schweitzer R, Khatib S, Magzal F, Muller E, Tamir S, Tenenbaum-Gavish K, Rautava S, Salminen S, Isolauri E, Yariv O, Peled Y, Poran E, Pardo J, Chen R, Hod M, Borenstein E, Ley RE, Schwartz B, Louzoun Y, Hadar E, Koren O. Gestational diabetes is driven by microbiota-induced inflammation months before diagnosis. *Gut*. 2023 May;72(5):918-928. doi: 10.1136/gutjnl-2022-328406. Epub 2023 Jan 10. PMID: 36627187; PMCID: PMC10086485.
 164. Zehner N, **Parsonnet J**. The efficacy of mandatory employee SARS-CoV2 screening following coronavirus diseases 2019 at a San Francisco biotech Company. Submitted for publication.
 165. Walter WA, Ley C, Hastie T, Ley RE, **Parsonnet J**. Use of a modified Michaelis-Menten equation to estimate growth from birth to 3 years in health full term babies. *BMC Medical Research Methodology* (in press).
 166. Levitt JE, Hedlin H, Duong S, Lu D, Lee J, Bunning B, Elkarra N, Pinsky BA, Heffernan E, Springman E, Moss RB, Bonilla HF, **Parsonnet J**, Zamanian RT, Langguth JJ, Bollyky J, Khosla C, Nicolls MR, Desai M, Rogers AJ. Evaluation of acebilustat, a selective inhibitor of leukotriene B4 biosynthesis, for treatment of outpatients with mild-moderate COVID-19 disease: A randomized, double-blind, placebo- controlled Phase 2 trial. *Clin Infect Dis*. 2023 Mar 30:ciad187. doi: 10.1093/cid/ciad187. Epub ahead of print. PMID: 36996150.
 167. Varkila M, Montez-Rath M, Salomon J, Yu X, Block G, Owens DK, Chertow GM, **Parsonnet J***, Anand S* (*equal contributors). Use of wastewater metrics to track COVID-19 transmission dynamics in the US. *JAMA Netw Open*. 2023 Jul 3;6(7):e2325591. doi: 10.1001/jamanetworkopen.2023.25591. PMID:37494040
 168. Anand S, Montez-Rath M, Varkila M, Yu X, Block M, Brillhart S, Leppink A, Hunsader P, Owens DK, Chertow GM, **Parsonnet J**, Block G. Feasibility and Acceptability of SARS-CoV-2 Screening among Patients Receiving Hemodialysis: A Pilot Study. *Clin J Am Soc Nephrol*. 2023 Mar 29;. doi: 10.2215/CJN.0000000000000137. [Epub ahead of print] PubMed PMID: 36976655.
 169. Ley C, Heath F, Hastie T, Gao Z, Protsiv M, **Parsonnet J**. Defining Usual Oral Temperature Ranges in Outpatients Using an Unsupervised Learning Algorithm. *JAMA Intern Med*. 2023;183(10):1128–1135. doi:10.1001/jamainternmed.2023.4291
 170. Nguyen KD, Haggerty TD, Röltgen K, Tolentino L, **Parsonnet J**, Pham TD, Boyd SD. Assessing SARS-CoV-2 Humoral Immune Status in Dried Blood Spot Specimens. Final preparation.

171. Ley C, Duan H, **Parsonnet J**. Recruitment into COVID antibody prevalence studies: a comparison of postcards vs. letters as invitations. *BMC Med Res Methodol*. 2023 Jul 22;23(1):170. doi: 10.1186/s12874-023-01992-8. PMID:37481522.
172. Bennett C, Detsky A, Clay C, Espinola J, **Parsonnet J**, Camargo C. Comparison of US Emergency Departments by HIV Priority Jurisdiction Designation: A Case for Geographically Targeted Screening in Teaching Hospitals. *PLoS One*. 2023 Oct 18;18(10):e0292869. doi: 10.1371/journal.pone.0292869. eCollection 2023. PMID:37851641.
173. Lim E, Mehrotra ML, Lamba K, Kamli A, Lai K, Meza E, Bertsch-Merbah S, Szeto I, Ley C, Martin AB, **Parsonnet J**, Robinson P, Gebhart D, Fonseca N, Tsai C, Seftel D, Nicolici A, Melton D, Jain S. The CalScope study: Methodology and lessons learned for conducting a remote statewide SARS-CoV-2 seroprevalence study in California using an at-home dried blood spot collection kit and online survey. *AJPH*. Submitted.
174. Zulli A, Varkila M, **Parsonnet J**, Wolfe MK, Boehm A. Observations of respiratory syncytial virus (RSV) nucleic-acids in wastewater solids across the United States in the 2022-2023 season: Relationships with RSV infection positivity and hospitalization rates. *ACS ES&T Water*. 2024. DOI: 10.1021/acsestwater.3c00725
175. Lee JJ, Kakuru A, Jacobson KB, Kamya MR, Kajubi R, **Parsonnet J**, Benjamin-Chung J, Dorsey G, Jagannathan P, Roh ME. Monthly sulfadoxine-pyrimethamine during pregnancy prevents febrile respiratory illnesses: a secondary analysis of a malaria chemoprevention trial in Uganda. *Open Forum Infectious Diseases*. In press.
176. Wolfe MK, Shelden B, Duong D, Varkila M, White B, Parsonnet J, Boehm A. Detection and quantification of human immunodeficiency virus-1 (HIV-1) total nucleic acids in wastewater settled solids from two California communities. *Applied and Environmental Microbiol*. Submitted for publication.

BOOKS

1. **Parsonnet J** (ed). Microbes and Malignancy: Infection as a Cause of Human Cancer. New York, Oxford University Press, 1999.

BOOK CHAPTERS

1. **Parsonnet J**. The epidemiology of *Campylobacter pylori* infection. In: Blaser MJ (ed). *Campylobacter pylori* in gastritis and peptic ulcer disease. New York, IgakuShoin, 1989; pp 51-60.
2. Gregg M, **Parsonnet J**. The principles of an epidemic field investigation. In: Holland WW, Detels R (eds). Oxford Textbook of Public Health. London, Oxford Medical Publications, 1991; pp 400-415.
3. **Parsonnet J**. Gastrointestinal microbiology. In: Lederberg J (ed). Encyclopedia of Microbiology, Volume 2. New York, Academic Press, 1992; pp 245-258.
4. **Parsonnet J**, Griffin PM. Hemolytic Uremic Syndrome: Clinical Picture and Bacterial Connection. In Remington JS, Swartz MN (eds). Current Clinical Topics in Infectious Diseases. New York, McGraw-Hill, 1993; pp 172-187.
5. Perez-Perez GI, **Parsonnet J**. Epidemiology of *Helicobacter pylori* infections. In: O'Morain CA, O'Connor H (eds). *Helicobacter pylori: implications and practice*. Bad Homburg, Normed Verlag, 1994; pp 52-57.

6. **Parsonnet J**, Wanke C, Hack H. Chronic diarrhea. In: Blaser MJ, Smith PD Ravdin JI et al (eds). Infections of the Gastrointestinal Tract. New York, Raven Press, 1995; pp 311-324
7. Taylor D, **Parsonnet J**. Epidemiology and natural history of *Helicobacter pylori* infection. In: Blaser MJ, Smith PD, Ravdin JI et al (eds). Infections of the Gastrointestinal Tract. New York, Raven Press, 1995; pp 551-564.
8. **Parsonnet J**. Lessons from the epidemiology of *H. pylori* and cancer. In: Hunt RH, Tytgat, GNJ (eds). Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers, 1996; pp 238-244.
9. **Parsonnet J**. *Helicobacter*. In: Gorbach SL, Bartlett JG, Blacklow NR (eds). Infectious Diseases. Philadelphia, W.B. Saunders, 1997; pp 1952-1961.
10. Smith K, **Parsonnet J**. *Helicobacter pylori*. In: Evans AS, Brachman PS (eds). Bacterial infections of humans: epidemiology and control. New York, Plenum Publishing Corporation 1998; pp 337-353.
11. Passaro D, **Parsonnet J**. Advances in the prevention and management of traveler's diarrhea. In Remington JS, Swartz MN (eds). Current Clinical Topics in Infectious Diseases. New York, Blackwell Science, 1998; pp 217-236.
12. **Parsonnet J**, Basch P. Tropical infectious diseases and malignancy. In: Guerrant RL, Krogstad DJ, Walker DH, Weller PF (eds). Tropical Infectious Diseases. New York, Churchill Livingstone 1999; pp 208-214.
13. **Parsonnet J**. *Helicobacter pylori* and gastric adenocarcinoma. In **Parsonnet J** (ed). Microbes and Malignancy: Infection as a Cause of Human Cancer. New York, Oxford University Press 1999; pp 372-408.
14. Infectious Causes of Cancer: Targets for Intervention. Totawa NJ, Humana Press 2000; pp 389-410.
15. **Parsonnet J**. Factors associated with disappearance of *H. pylori* in the west. In: Hunt RH, Tytgat, GNJ (eds). Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers, 2000; pp 45-52.
16. Sobel J, Swerdlow D, **Parsonnet J**. Is anything safe to eat? Current Clinical Topics in Infectious Diseases. New York, Blackwell Science 2001; pp 114-134.
17. **Parsonnet J**, Mintz, ED, Wanke C. Chronic diarrhea. In: Blaser MJ, Smith PD Ravdin JI, et al (eds). Infections of the Gastrointestinal Tract. 2nd Edition. New York, Lippincott Williams & Wilkins 2002; pp 267-279.
18. **Parsonnet J**. *Helicobacter*. In: Gorbach SL, Bartlett JG, Blacklow NR (eds). Infectious Diseases. Philadelphia, W.B. Saunders 2002; pp 1837-1842.
19. **Parsonnet J**. What is the *Helicobacter pylori* global reinfection rate? In: Hunt RH, Tytgat, GNJ (eds). Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers 2003; pp 339-345.
20. Tsai CJ, **Parsonnet J**. Are there reliable non-invasive approaches to assessing gastritis for epidemiologic studies? In: Hunt RH, Tytgat, GNJ (eds). Helicobacter pylori: Basic mechanisms to clinical cure. Dordrecht, Kluwer Academic Publishers 2003; pp 149-160.
21. Herrera LA, Davis Y, **Parsonnet J**. Primary Gastric Lymphoma. In: Bayless TM (ed). Advanced Therapy of Gastroenterology and Liver Disease. Philadelphia, BC Decker, Inc. 2005;202-6.
22. Mueller NE, Birmann B, **Parsonnet J** Schiffman M, Stuver S. Infectious Agents. In: Schottenfeld D, Fraumeni JF (eds). Cancer Epidemiology and Prevention. New York, Oxford University Press 2006; pp. 507-48.
23. Shibata A, **Parsonnet J**. Stomach cancer. In: Schottenfeld D, Fraumeni JF

- (eds). Cancer Epidemiology and Prevention. New York, Oxford University Press 2006; pp.707-720.
24. DeMartel C, **Parsonnet J**. Tropical infectious diseases and malignancy. In: Guerrant RL, Krogstad DJ, Walker DH, Weller PF (eds). Tropical Infectious Diseases, 2nd Edition. Philadelphia, Elsevier 2006; pp 135-141.
 25. Fox JG, Wang T, **Parsonnet J**. *Helicobacter pylori*. In zur Hausen (ed). Infections Causing Human Cancer. Weinheim, Wiley VCH 2006; pp. 386-467.
 26. Duensing S, Moore PM, **Parsonnet J**. Infectious Agents and Cancer. In: Allison MR (ed). The Cancer Handbook. Second Edition. New York, Wiley. 2007; pp. 372-87.
 27. **Parsonnet J** *Helicobacter pylori*. In: Brachman PS and Abrutyn E. (eds). Bacterial infections of humans: epidemiology and control. New York, Springer 2009; pp 369-394.
 28. Volkerman J, **Parsonnet J**. Epidemiology of gastric cancer and *H. pylori*. In: Wang T, Fox J, Giraud A (eds). Biology of Gastric Cancer, New Yorks, Springer Press 2009; pp.25-58.
 29. **Parsonnet J**. Tropical infectious diseases and malignancy. In: Guerrant RL, Krogstad DJ, Walker DH, Weller PF (eds). Tropical Infectious Diseases, 3rd Edition. Philadelphia, Elsevier. 2011 pp76-94.
 30. DeMartel C, **Parsonnet J**. Stomach cancer. In: Thun JM, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D (eds). Cancer Epidemiology and Prevention. New York, Oxford University Press. 2017 pp. 593-610
 31. Nelson J, **Parsonnet J**. Bacterial lung abscess. In: Bennett JE, Dolin R, Blaser MJ (eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 9th Edition. Philadelphia, Elsevier. 2020; pp 926-931
 32. Nelson J, **Parsonnet J**. Bacterial lung abscess. In: Dolin R and Blaser MJ (eds). Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, 10th Edition; submitted.
 - 33.

BOOK REVIEWS

1. **Parsonnet J**. *Helicobacter pylori: Biology and Clinical Practice*. *New England Journal of Medicine* 1994; 330:1625-1626.
2. **Parsonnet J**. The Enemy Within. Plague time: How Stealth Infections Cause Cancers, Heart Disease, and Other Deadly Ailments. *American Scientist* 2001; 89:3.

PATENTS

1. Chiu C, Yu G, Greninger A, Isa P, Arias CF, De Risi J, Parsonnet J, Miller S. inventors; Regents of the University of California, assignee. Novel polyomavirus associated with diarrhea in children. United States patent US20140065599 A1. 2014 March 6 (pending)

INVITED PRESENTATIONS (selected plenary talks and visiting professorships among >100 invited talks)

1. Keynote Speaker, "Infection, inflammation and cancer". International Symposium of Sapporo Cancer Seminar. Sapporo, Japan. July 1996

2. Plenary speaker, “*Helicobacter pylori* and the stomach: a complex coexistence leading to cancer”. Infectious Diseases Society of America. September 1996
3. Plenary Speaker, “Microbes and Malignancy” International Immunocompromised Host Society, Davos, Switzerland, July 1998
4. Plenary Speaker, “*H. pylori* and gastric cancer.” Danish Gastroenterology Society, Copenhagen, Denmark. September 2000.
5. H.H. Chao Visiting Professor. Asian-American Cancer Outreach and Research Program. University of California, Irvine. January 2001.
6. Pfizer Visiting Professor in Infectious Diseases, Baylor College of Medicine, November 2001.
7. Plenary Speaker, “Just one bug: *H. pylori* and the complexity of chronic infections.” International Conference on Emerging Infectious Diseases, Atlanta, Georgia. March 2004.
8. Guest speaker, International Agency for Research on Cancer, July 2009.
9. Maxwell Finland Lecture, “Infectious Diseases Epidemiology and Chronic Disease”, Infectious Diseases Society of America, October 2011
10. Hans L. Falk Memorial Lecture, “Spirits in the Microbial World”. NIEHS, March 2013.
11. Invited speaker, Max Planck Institute, Tübingen, Germany. “Spirits in the Microbial World”. November, 2017
12. Plenary speaker, International Hypothermia and Temperature Management Symposium 2022, Eindhoven, Netherlands
13. Keynote speaker, March, 2023 Harvard-wide Infectious Disease training program Retreat
14. Visiting Professor in Microbiology and Immunology, May 2023, University of California, Irvine.

REFEREED INVITED PAPERS

1. ***Parsonnet J.** Bacterial infection as a cause of cancer. *Environment Health Perspective* 1995; 103(Suppl 8):263-268.
2. ****Parsonnet J.** The incidence of *Helicobacter pylori* infection. *Alimentary Pharmacology and Therapeutics* 1995; 9:45-52.
3. **Parsonnet J**, Axon AT. Principles of screening and surveillance. *American Journal of Gastroenterology* 1996; 91:847-849.
4. **Parsonnet J.** Molecular mechanisms for inflammation-promoted pathogenesis of cancer: The Sixteenth International Symposium of the Sapporo Cancer Seminar. *Cancer Research* 1997; 57:3620-3624.
5. ***Parsonnet J.** *Helicobacter pylori*: the size of the problem. *Gut* 1998; 43(suppl 1):S6-S9. PMID:PMC1766594.
6. *****Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappouli R.** *Helicobacter pylori*, virulence and genetic geography. *Science* 1999; 284:1328-1333.
7. ***Chang, AH, Parsonnet J.** Role of bacteria in oncogenesis. *Clin Microbiol Rev.* 2010;23:837-57. PMID: 20930075.
8. ***Herrera V, Perry S, Parsonnet J, Banaei N.** Clinical application and limitations of interferon-gamma release assay for the diagnosis of latent tuberculosis infection. *Clin Infect Dis* 2011;15:1031-7. PMID:21460320.

9. Perry S, Hussain R, **Parsonnet J**. The impact of mucosal co-infections on M.tuberculosis acquisition and progression. *Mucosal Immunol*. In press.
10. Huang RJ, Koh H, Hwang JH, Summit Leaders. A summary of the 2020 gastric cancer summit at Stanford University. *Gastroenterology* 2020;159:1221-6. PMID 32707045

LETTERS TO THE EDITOR

1. Friedman GD, **Parsonnet J**. Salt intake and stomach cancer: some contrary evidence. *Cancer Epidemiology, Biomarkers and Prevention* 1992; 1:607-608.
2. Stommel EW, Jenkyn LR, **Parsonnet J**. Another case of polymyositis after ciguatera toxin exposure. *Archives of Neurology* 1993; 50:571.
3. Mintz E, **Parsonnet J**, Osterholm M. Chronic idiopathic diarrhea. *New England Journal of Medicine* 1993; 328:1713-1714.
4. Hack HM, **Parsonnet J**, Triadafilopoulos G. Testing negative for *Helicobacter pylori* after methylene blue spraying of gastric mucosa. *Gastrointestinal Endoscopy* 1994; 40:397-398.
5. **Forman D, Webb P, **Parsonnet J**. *H. pylori* and gastric cancer. *Lancet* 1994; 343:243-244.
6. **Parsonnet J**, Hansen S, Friedman GD. *Helicobacter pylori* and gastric lymphoma. *New England Journal of Medicine* 1994; 331:746.
7. **Parsonnet J**. *Helicobacter pylori*, gastric ulcer and duodenal ulcer--Reply. *New England Journal of Medicine* 1996; 335; 1842-3 .
8. Smith K, **Parsonnet J**. Association between prior cytomegalovirus infection and risk of restenosis after coronary atherectomy. *New England Journal of Medicine* 1997; 336:587.
9. De Arruda SM, Passaro DJ, **Parsonnet J**. Variability of serologic testing for *H. pylori* using U.S. and Peruvian antigens. *Gastroenterology* 2001; 120:325-326.
10. Ley C, **Parsonnet J**. *Helicobacter pylori* infection and gastric cancer. *Gastroenterology* 2001; 120:324-325.
11. Shibata A, **Parsonnet J**, Longacre TA, Garcia MI, Puligandla B, Davis RE, Vogelman JH, Orentreich N, Habel LA. CagA status of *Helicobacter pylori* infection and p53 gene mutations in gastric adenocarcinoma. *Carcinogenesis* 2003; 24:147.
12. Forman D, **Parsonnet J**. Dietary Risk Factors for Gastric Carcinoma-Reply. *Journal of American Medical Association* 2004; 291:1564.
13. Pischel L, Poole AC, Ley C, Suh G, Goodrich JK, Haggerty TD, Ley RE, **Parsonnet J**. Reply to "Triclocarban and Health: the Jury Is Still Out". mSphere. 2016 Nov 2;1(6). pii: e00255-16. eCollection 2016 Nov-Dec. PMID: 27841373; PMCID: PMC5093150.
14. Anand S, Montez-Rath M, Han J, Cadden LC, Hunsader P, Kerschmann R, Beyer P, Boyd S, Garcia P, Dittrich M, Block GA, **Parsonnet J**, Chertow G. SARS-COV-2 antibody prevalence in patients on dialysis in the USA in January 2021. *The Lancet*. 2021
15. Epidemic Intelligence Service Officers Past and Present. Open Letter by Epidemic Intelligence Service Officers Past and Present - in Support of CDC. *Epimonitor*. 2020 Oct;41(10):12-18. Epub 2020 Oct 14. PMID: 33345259; PMCID: PMC7748252.

OTHER PUBLICATIONS

1. **Parsonnet J.** Gastric cancer, preneoplasia and *Helicobacter pylori*. Clinical Advances in Gastroenterology [Cassette tape]. Volume 6, Number 4.
2. ****NIH Consensus Development Panel on *Helicobacter pylori* in Peptic Ulcer Disease** (one of many 100 authors). *Helicobacter pylori* in Peptic Ulcer Disease. JAMA 1995;272:65-9.
3. **Parsonnet J.** Stomach cancer. In: Glaser SJ, Satariano ER, Leung RW, Prehn AW, Cady CM West DW (eds). Cancer Incidence by Race/Ethnicity in the San Francisco-Oakland Area: Twenty years of cancer reporting, 1973-1992. Monograph of the Northern California Cancer Center 1996; pp 64-65.
4. Park JY, Greenberg ER, **Parsonnet J**, Wild CP, Forman D, Herrero R. Summary of IARC Working Group Meeting on *Helicobacter pylori* eradication as a strategy for preventing gastric cancer. **IARC *Helicobacter pylori* Working Group** (2014). *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). pp 1-4. Available from: <http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php>
5. **Parsonnet J.** Are there benefits of *Helicobacter pylori* eradication? (2014). *Helicobacter pylori* Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, No. 8). pp 72-79. Available from: <http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php>

INVITED EDITORIALS/PERSPECTIVES

1. ***Parsonnet J.** *Helicobacter pylori* in the stomach - A paradox unmasked. *New England Journal of Medicine* 1996; 335:278-280.
2. Streett S, **Parsonnet J.** *H. pylori*: an infectious pathogen. *Infectious Diseases and Clinical Practice* 1997; 6:27-28.
3. **Parsonnet J.** When heredity is infectious. *Gastroenterology* 2000; 118:222-225.
4. ***Parsonnet J, Isaacson PG.** Bacterial infection and MALT lymphoma. *New England Journal of Medicine* 2004;213-215.
5. **Parsonnet J, Forman D.** *Helicobacter pylori* infection and gastric cancer – For want of more outcomes. JAMA;291:244-5.
6. Perry S, **Parsonnet J.** Commentary: *H. pylori* infection in early life and the problem of imperfect tests. *International Journal of Epidemiology*.2005;34:1356-8.
7. Herrero R, **Parsonnet J**, Greenberg ER. Prevention of gastric cancer. JAMA. 2014;312:1197-8.
8. **Parsonnet J.** Time for *Helicobacter pylori* eradication. *Lancet Infectious Diseases*. 2019;19:1042-1043. PMID: 31559950

INVITED ARTICLES

1. **Parsonnet J.** Bacteriologic analysis of clinical specimens in waterborne disease outbreaks. In Craun GF (ed): Methods for the Investigation and Prevention of Waterborne Disease Outbreaks. Cincinnati, U.S. Environmental Protection Agency 1990; pp 235-242.
2. ****Parsonnet J.** *Helicobacter pylori* and gastric cancer. *Gastroenterology Clinical North American* 1993; 22:89-104.

3. **Parsonnet J.** *Helicobacter pylori* as a risk factor for gastric cancer. *Europe Journal of Gastroenterology/Hepatology* 1993; 5(suppl):S103-107.
4. **Parsonnet J.** Gastric adenocarcinoma and *Helicobacter pylori* infections. *Western Journal of Medicine* 1994; 161:60.
5. Streett S, **Parsonnet J.** *H. pylori* as a carcinogen: potential mechanisms of pathogenesis in gastric adenocarcinoma. *Infectious Agents and Disease* 1996.
6. **Parsonnet J.** *Helicobacter pylori*. *Infectious Disease Clinical North American* 1998; 12:185-198.
7. Asghar RJ, **Parsonnet J.** *H. pylori* and risk for adenoacarcinoma. *Seminars in Gastroenterology* 2001.
8. Passaro DJ, Chosey EJ, **Parsonnet J.** *H. pylori*—consensus and controversy. *Clinical Infectious Diseases* 2002; 35:298-304.
9. Davies Y, **Parsonnet J.** The relationship between *Helicobacter pylori* and adenocarcinoma. *Clinical Laboratory International* 2002; 26:8-12.
10. **Parsonnet J.** Clinician discoverers — Marshall, Warren and *H. pylori*. *New England Journal of Medicine* 2005; 353:2421-2423.
11. *Herrera V, **Parsonnet J.** *Helicobacter pylori* and gastric adenocarcinoma. *Clin Microbiol Infect* 2009;15:971-6.
12. Nolen LD, Vindigni SM, **Parsonnet J;** Symposium leaders. Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium. *Gastroenterology*. 2020;158:1197-1201. PMID: 31836529; PMCID: PMC7103478.